Today, scientists presented final results from our Phase I clinical trial of ALN-TTRo1 at the XIII International Symposium on Amyloidosis held in Groningen. Data from this study show that administration of ALN-TTR01 resulted in statistically significant reductions in serum TTR protein levels, including both wild-type and mutant TTR protein, in ATTR patients. Knockdown of TTR, the disease-causing protein, was found to be dose dependent, rapid, and durable after just a single dose.
View our presentation (842 KB PDF) View our release Listen to KOL, Dr. Hawkins discuss the ALN-TTR program (recorded Jan. 2012) (27.7MB MP3)April 20, 2012
Positive Clinical Results for ALN-PCS, Reported at ATVB 2012
Yesterday, scientists presented positive results from our Phase I clinical trial of ALN-PCS at the American Heart Association’s Arteriosclerosis, Thrombosis and Vascular Biology 2012 Scientific Sessions held in Chicago. Results showed that administration of a single dose of ALN-PCS, in the absence of concomitant lipid-lowering agents such as statins, resulted in statistically significant and durable reductions of PCSK9 plasma levels of up to 84% and lowering of LDL-C of up to 50%.
View our presentation (572 KB PDF) View our release (572 KB PDF)March 1, 2012
Delivery Strategies for RNAi Therapeutics
Our scientists presented an update on our RNAi delivery strategies at the AsiaTIDES conference this week. The presentation focuses on our recent progress utilizing conjugates and lipid nanoparticles for systemic adminstration of RNAi therapeutics.
View our presentation (2.4MB PDF)February 9, 2012
Novel Method for Monitoring RNAi Activity in Blood Samples
Our scientists discovered a new method for monitoring RNAi activity in blood samples. The results were presented at the Keystone Gene Silencing by small RNAs symposium (Vancouver, February 7-12). This new method, circulating extracellular RNA detection (cERD), allows quantitative measurement of tissue-specific mRNA silencing from biological fluids including blood and cerebrospinal fluid (CSF).
View our poster (1.18 MB PDF) Read our press releaseJanuary 11, 2012
Alnylam Corporate Overview, January 2012
December 13, 2011
Alnylam Scientists Present New Data on RNAi Therapeutics at 53rd ASH Annual Meeting
In December 2011, our scientists presented multiple posters and presentations at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition held in San Diego, CA. We shared data from two programs within our “Alnylam 5×15” product pipeline, including pre-clinical data from ALN-APC, an RNAi therapeutic targeting protein C for the treatment of hemophilia,…
View the refractory anemia presentation (680 KB PPT) View the hemophilia poster (1.88 MB PDF) View the beta-thalassemia poster (112 KB PDF) View the erythropoiesis poster (435 KB PDF) Read our press releaseSeptember 12, 2011
New Delivery Advances at 2011 OTS Meeting
In September 2011, we and our collaborators presented new data at the 7th Annual Meeting of the Oligonucleotide Therapeutics Society demonstrating substantial new advances in our efforts around systemic delivery of RNAi therapeutics.
View the LNP Poster (2.1 MB PPT) View the Conjugate Poster (3.1 MB PPT) Read our press releaseSeptember 8, 2011
ALN-APC for Hemophilia
We have launched our fourth program as part of our Alnylam 5×15 product development strategy. ALN-APC is an RNAi therapeutic for the treatment of hemophilia, and as with our other Alnylam 5×15 programs, targets protein C, a genetically defined target, and will utilize Alnylam’s existing delivery platform.
Read our press release Listen to our CMO discuss the hemophilia program (13.3MB mp3) View the slides (1.5MB PPT)July 23, 2011
ALN-TTR Data Presented at Peripheral Nerve Society Meeting
Our flagship effort from the Alnylam 5×15 strategy is our ALN-TTR program, which is currently enrolling patients in a Phase I study for the treatment of a disease called transthyretin-mediated amyloidosis (ATTR).
Read our press release ALNY-PNS-Poster-ALN-TTR-NT-Study-June2011 (720KB PPT) ALNY-PNS-Poster-ALN-TTR-June2011 (1.1MB PPT)ALN-TTR RNAi Roundtable, July 2010 (1.0 MB PPT) Continue reading…
June 29, 2011
ALN-VSP Data at 2011 ASCO Meeting
At the ASCO Annual Meeting in June 2011, we presented complete results from our Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of patients with advanced solid tumors with liver involvement.
Read our press release ALN-VSP PhI ClinicalStudyResults-ASCO2011 (1.2MB PPT) ALN-VSP RNAi Roundtable, May 2011 (2.2 MB PPT) Listen to Dr. Jared Gollob discuss ALN-VSP data at ASCO 2011 (3.1MB MP3)